How to Value a Medical Device Company in 2026

Medical device is one of the most nuanced sectors I work in. I've advised on transactions ranging from a single-product orthopedic implant company that sold for 3x revenue to a multi-product diagnostics platform that commanded 18x EBITDA. The spread is enormous, and the drivers behind it are almost entirely specific to this industry.

Across 1,004 medical device transactions in our database, the median EBITDA multiple is 14.1x and the median revenue multiple is 2.84x. But those headline numbers mask a dramatic range. Under $5M in enterprise value, you're looking at 9.1x EBITDA and 1.0x revenue. At $5-25M, it tightens to 8.4x EBITDA and 1.6x revenue. The sector is consolidating aggressively, and understanding what drives the spread is worth real money at exit.

FDA Classification Changes Everything

If there's one thing that separates medical device valuation from general manufacturing valuation, it's the regulatory pathway. The FDA classifies devices into three categories, and each one carries fundamentally different risk profiles, timelines, and barriers to entry.

Class I devices(tongue depressors, bandages, exam gloves) are exempt from premarket review. They're essentially commodity products. Margins are thin, competition is fierce, and multiples reflect that — typically 4-7x EBITDA. There's no regulatory moat.

Class II devices(surgical instruments, powered wheelchairs, pregnancy tests) require 510(k) clearance — demonstrating substantial equivalence to a legally marketed predicate device. This is where most of the mid-market M&A activity happens. A cleared 510(k) is a transferable asset, and buyers value the 6-12 month timeline and $50-150K cost they don't have to spend to get clearance themselves. Multiples: 8-14x EBITDA depending on product category and competitive landscape.

Class III devices(pacemakers, coronary stents, artificial hearts) require Premarket Approval (PMA) — the most stringent pathway, involving clinical trials, years of development, and $30-75M+ in regulatory costs. PMA-approved devices command the highest multiples because the barriers are nearly insurmountable for competitors. I've seen PMA-stage companies trade at 15-25x EBITDA or 5-8x revenue in strategic acquisitions. The regulatory clearance itself becomes the primary asset.

Revenue Model: Disposables vs. Capital Equipment

The second major valuation driver is how the company generates revenue, and this is where I see sellers most often undervalue themselves — or overestimate their worth.

Disposables and consumables (surgical supplies, test strips, single-use instruments) generate recurring revenue. Once a hospital integrates your disposable into their supply chain, switching costs are real — staff training, protocol changes, committee approvals. Buyers pay a premium for this stickiness because they can model predictable forward revenue. Companies with 70%+ of revenue from disposables routinely earn a recurring revenue premium of 20-40% over comparable capital equipment companies.

Capital equipment(imaging systems, surgical robots, therapy devices) generates lumpy, large-ticket revenue. A single deal can make or break a quarter. Buyers discount this volatility, and they worry about sales pipeline concentration. If three hospital systems represent 60% of your annual orders, that's a concentration risk that compresses multiples. Capital equipment companies typically trade at 6-10x EBITDA unless they've built a meaningful service contract or aftermarket parts business alongside the hardware.

The companies that command the highest multiples have figured out the razor-and-blade model — sell the capital equipment at modest margins, then generate high-margin recurring revenue from consumables, service contracts, and software subscriptions tied to the installed base. I worked on a surgical device company that had 40% of revenue from instrument refurbishment and consumable kits. That recurring component added nearly 3x to the EBITDA multiple versus a pure capital equipment comparable.

Reimbursement: The Hidden Valuation Driver

Many device company founders are engineers or clinicians who underestimate how much buyers care about the reimbursement landscape. A device can be clinically superior and still be nearly worthless if payers won't reimburse for it.

The key questions buyers ask:

• Does the device have assigned CPT and HCPCS codes? Existing reimbursement codes mean hospitals can bill for procedures using your device without navigating the CMS coding process (which takes 18-36 months).
• What's the reimbursement level? Higher reimbursement per procedure means hospitals are incentivized to adopt your technology. If the DRG payment exceeds the device cost by a meaningful margin, adoption is almost automatic.
• Is reimbursement at risk? CMS coverage decisions, prior authorization requirements, and payer pushback on new technologies can destroy the economic case for a device overnight.
• Does the device reduce total cost of care? In value-based reimbursement models, devices that demonstrably reduce hospital stays, readmissions, or complications command premiums because they align with where payment models are heading.

I once walked away from a deal on a wound care device company because their primary product relied on a pass-through payment that CMS was reviewing for expiration. The company had strong revenue, but the reimbursement risk made the forward projections too uncertain for my buyer to underwrite.

IP Portfolio and Clinical Data

In medical devices, intellectual property isn't just a legal defense — it's a core asset that directly impacts how buyers value your business. Strategic acquirers (Medtronic, J&J, Stryker, Boston Scientific) are often buying the IP portfolio as much as the revenue stream.

What makes an IP portfolio valuable in this space:

• Patent breadth and remaining life: Utility patents with 10+ years remaining and broad claims are worth more than narrow design patents expiring in 3 years.
• Freedom to operate: A clean FTO opinion means the acquirer won't inherit patent litigation risk. Unresolved IP disputes can tank a deal or lead to massive escrow holdbacks.
• Trade secrets and manufacturing know-how: Some of the most defensible medical device companies have proprietary manufacturing processes that are nearly impossible to reverse-engineer, even without patent protection.
• Clinical data: Peer-reviewed publications, prospective clinical studies, and registry data demonstrating safety and efficacy are enormously valuable. They take years and millions to generate, and a strategic acquirer can leverage them immediately.

The companies with the strongest IP portfolios often receive acquisition offers well above comparable multiples because the acquirer is buying time-to-market and clinical validation that would cost them 5-10x more to develop internally.

Distribution Model and Customer Concentration

How you get your product to end users matters more than most device founders appreciate.

Direct sales force: Higher margins, deeper customer relationships, better market intelligence. But expensive to maintain and hard to scale. Companies with effective direct sales organizations in specialized niches (spine, cardiac, ophthalmology) command premium multiples because the sales team and surgeon relationships transfer with the acquisition.

GPO/IDN contracts: Group Purchasing Organizations (Vizient, Premier, HealthTrust) and Integrated Delivery Networks provide volume but compress margins. A GPO contract with favorable tier positioning is a valuable asset — it gives buyers instant distribution. But dependency on a single GPO contract is a risk.

Distributor networks: Third-party distributors (Cardinal Health, Owens & Minor, Henry Schein) provide reach without headcount. The downside is margin erosion (25-40% distributor markup) and loss of customer relationships. Companies transitioning from distributor to direct sales often see multiples expand as margins improve and they build direct hospital relationships.

Customer concentration is a deal-killer in device M&A. If a single hospital system or GPO contract represents more than 20% of revenue, expect buyers to apply a discount. I've seen deals repriced 15-25% when diligence revealed that one IDN relationship was driving the growth story.

The Single-Product Risk Discount

This is the most common valuation gap I encounter in device company sales. Founders who've spent a decade perfecting one product are understandably proud of it. But buyers see single-product risk, and they price it accordingly.

A company with one product is one adverse event report, one competitive launch, or one reimbursement change away from a catastrophic revenue decline. Multi-product platforms with shared distribution infrastructure consistently trade at 30-50% premiums over single-product companies at the same revenue level.

If you're a single-product company planning to sell in the next 2-3 years, the highest-ROI activity is often launching adjacent products — line extensions, complementary consumables, or next-generation versions — that demonstrate the platform potential of your technology and distribution channel.

Who's Buying and What They Pay

The medical device M&A landscape is dominated by a handful of strategic acquirers and an increasingly active PE community.

Strategic acquirers(Medtronic, Abbott, Boston Scientific, Stryker, Becton Dickinson, Zimmer Biomet) pay the highest multiples when your technology fills a portfolio gap or extends their presence in a high-growth segment. They can justify 15-20x+ EBITDA because they'll distribute your product through their existing sales force and extract synergies immediately.

PE-backed platforms are increasingly active in the $10-100M enterprise value range. They're building specialty platforms through buy-and-build strategies, typically paying 8-12x EBITDA for platform acquisitions and 6-9x for add-ons. The advantage of selling to a PE platform is that you may retain equity and participate in a second exit at a higher multiple.

Smaller strategics and emerging growth companies acquiring to fill product gaps or enter new clinical areas. These buyers typically pay 6-10x EBITDA and can close faster than large strategics because they have fewer integration committees and regulatory review processes.

The Bottom Line

Medical device valuation sits at the intersection of regulatory complexity, clinical evidence, and commercial execution. The companies that command the highest multiples have cleared meaningful regulatory hurdles, built recurring revenue streams around their technology, generated strong clinical data, and diversified beyond a single product.

If you're building toward an exit, the playbook is clear: invest in clinical evidence, expand your product portfolio, build direct customer relationships, and secure your IP position. Those four things have more impact on your eventual multiple than any amount of revenue growth in isolation.